First human test for new heart failure fluid drug
NCT ID NCT06506994
Summary
This early-stage study tested the safety and effects of a new injectable drug, HRS-9057, in people with heart failure who had too much fluid in their bodies despite taking water pills. It involved 25 participants who received either the new injection or a standard pill (tolvaptan) to see how their bodies handled the drug and if it helped remove extra fluid. The main goal was to check for side effects and see how the drug moved through the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH VOLUME OVERLOAD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510285, China
Conditions
Explore the condition pages connected to this study.